

1 **Title:** Evaluation of a training course for general practitioners within the Melanoma Multimedia Education  
2 Programme of the Italian Melanoma Intergroup: study protocol

3

4 **Authors:**

5 Ignazio Stanganelli<sup>1,2</sup>, Serena Magi<sup>1</sup>, Lauro Bucchi<sup>3</sup>, Emanuele Crocetti<sup>3</sup>, Silvia Mancini<sup>3</sup>, Rosa Vattiato<sup>3</sup>, Stefano  
6 Falcinelli<sup>4</sup>, Patrizia Re<sup>4</sup>, Davide Melandri<sup>5</sup>, Marco Brusasco<sup>6</sup>, Sara Gandini<sup>7</sup>, Fabio Falcini<sup>3,8</sup> Federica Zamagni<sup>3</sup>  
7 and the FAD MelaMEd Working Group

8

9 **Affiliations:**

10 <sup>1</sup>Skin Cancer Unit, Romagna Cancer Institute, IRCCS IRST Istituto Romagnolo per lo Studio dei Tumori (IRST)  
11 "Dino Amadori", Meldola, Forlì-Cesena, Italy

12 <sup>2</sup>Division of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy

13 <sup>3</sup>Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei  
14 Tumori (IRST) "Dino Amadori", Meldola, Forlì-Cesena, Italy

15 <sup>4</sup>General Practitioner, district of Ravenna, AUSL Romagna, Ravenna, Italy

16 <sup>5</sup>Division of Dermatology Cesena/Forlì AUSL Romagna and Department of Medicine and Surgery, University  
17 of Bologna, Italy

18 <sup>6</sup>Dermatology Unit, ASST Santi Paolo e Carlo, Milan, Italy

19 <sup>7</sup>Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy

20 <sup>8</sup>Cancer Prevention Unit, ASL Forlì, Forlì-Cesena, Italy

21 **Corresponding Author:**

22 Federica Zamagni

23 Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei  
24 Tumori (IRST) "Dino Amadori", via Piero Maroncelli 40, 47014, Meldola (FC), Italy.

25 [federica.zamagni@irst.emr.it](mailto:federica.zamagni@irst.emr.it) - Tel. +39 0543 739464

26 **Key Words:**

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Melanoma, study protocol, multimedia education, diagnosis, prevention

28 **Contributions:**

29 Ignazio Stanganelli and Federica Zamagni conceived this article and drafted the manuscript.

30 Marco Brusasco, Lauro Bucchi, Emanuele Crocetti, Stefano Falcinelli, Fabio Falcini, Sara Gandini, Serena Magi,

31 Davide Melandri, Silvia Mancini, Patrizia Re, Rosa Vattiato revised the manuscript critically for important

32 intellectual content. All authors read and approved the final version of the manuscript.

33

34 **Conflict of interest:**

35 The authors declare no potential conflict of interest.

36

37 **Ethics approval:**

38 The study design complied with the Declaration of Helsinki ethical standards and was approved by the Ethics

39 Committee at the Romagna Cancer Institute (ID: IRST100.37; IRST identifier codes: L4P3037, wfn.27L4). The

40 study was approved by the Scientific Committee of the Italian Melanoma Intergroup (IMI).

41

42 **Funding:**

43 This work was partly supported thanks to the contribution of Ricerca Corrente by the Italian Ministry of Health

44 within the research line “Appropriateness, outcomes, drug value and organizational models for the continuity

45 of diagnostic-therapeutic pathways in oncology”.

46 **Abstract**

47

48 The text discusses the role of general practitioners (GPs) in the prevention and early diagnosis of melanoma,  
49 a type of skin cancer. It highlights the need for GPs to be able to recognize suspicious skin lesions and refer  
50 patients to specialist dermatology centers. However, many GPs lack comprehensive training in diagnosing  
51 melanoma. The text mentions that various training courses have been conducted for GPs, but their impact  
52 on clinical practice has been limited.

53

54 The "MelaMED Programme" is an e-learning course developed by the Italian Melanoma Intergroup (IMI). The  
55 program aims to provide GPs with comprehensive knowledge of melanoma prevention, diagnosis, and  
56 treatment. It includes an e-learning section and a dedicated platform called MelaMED platform, which offers  
57 a multimedia atlas of melanoma.

58

59 The objective of the study is to evaluate the impact of the MelaMED programme on GPs' diagnostic accuracy,  
60 knowledge of melanoma, and management of suspicious lesions. The methodology involves administering  
61 pre-training and post-training questionnaires to participants, assessing their diagnostic skills and evaluating  
62 the training course's effectiveness.

63

64 The study aims to demonstrate the effectiveness of the MelaMED programme in improving GPs' ability to  
65 recognize and manage melanoma. It also seeks to identify areas for improvement and recommend  
66 interventions to enhance diagnostic accuracy. The results will be analyzed statistically using descriptive,  
67 univariate, and multivariate analysis methods.

## 68 1. RATIONALE AND BACKGROUND INFORMATION

### 69 1.1 The role of general practitioners in the prevention of melanoma

70 Several public information and education initiatives on self-skin surveillance have been carried out in many  
71 European nations throughout the years. Although very confusing, these initiatives have shown to significantly  
72 improve the time to diagnosis and survival from cutaneous melanoma.<sup>1</sup>

73 The primary prevention for skin malignancies, the clinical recognition of "suspicious melanoma" and the  
74 identification of patients at risk of melanoma are the recommended strategies by Europe's Beating Cancer  
75 Plan<sup>2</sup> and by Italian and international guidelines.<sup>3-6</sup>

76 According to these recommendations, general practitioners (GPs) and also paediatricians play an active role  
77 in the referral pathway to the dermatology center. Being the natural "link" between patients and the  
78 specialist reference centers, GPs must be able to recognize the skin lesions with clinical-morphological  
79 characteristics that are consistent with early-stage melanoma. Additionally, they must be at least somewhat  
80 familiar with the entire fundamental melanoma diagnostic-therapeutic pathway. In other words, their role is  
81 mainly to select to high-risk population and perform a preliminary differential diagnosis, i.e., to select  
82 patients susceptible to specialist diagnostic investigation. Nonetheless, many GPs lack of comprehensive  
83 training in diagnosis, patient selection, and the diagnostic-therapeutic pathway for skin malignancies,  
84 especially melanoma.

85 A recent review has collected the results of training courses for GPs on melanoma prevention. Interventions  
86 were heterogeneous and varied widely in the design and teaching methods, with live or online courses lasting  
87 from 5 minutes to 24 months.<sup>7</sup> Whilst several initiatives have demonstrated significant improvements in  
88 melanoma knowledge and expertise, only a few studies have revealed positive changes in clinical practice  
89 through histological review.<sup>7</sup>

90 The adequate triage of skin lesions and the knowledge of the essential basis of the melanoma diagnostic-  
91 therapeutic pathway allow an effective and efficient cooperation between GPs and specialist structures.  
92 According to the Italian Oncology Plan 2023-2027, the training of healthcare workers is considered "one of  
93 the best investments to guarantee high levels of performance" and "highly dynamic training interventions  
94 are recommended because they concern a continuously evolving sector with regards to care models,

95 technological innovations and the indispensable aspects of humanization and respect for the person".<sup>8</sup> For  
96 these reasons, the importance of multimedia technologies in education has been highlighted and the  
97 widespread adoption of multimedia e-learning tools has been recommended. In Italy, the effect of formal  
98 training on GP has been seldom evaluated and the impact of multimedia educational programme has never  
99 been investigated.<sup>9,10</sup>

## 100 **1.2 The “MelaMED Programme” and the evaluation of its training impact**

101 The Melanoma Multimedia Education (MelaMED programme), one of the projects developed by the Italian  
102 Melanoma Intergroup (IMI), aims to provide physicians, mainly general practitioners, with a comprehensive  
103 understanding of the primary and secondary prevention of cutaneous melanoma and a broad overview of  
104 diagnostic and therapeutic procedures. The MelaMED programme is hosted on a dedicated platform: an  
105 educational area which includes an e-learning section, with training courses accrediting Continuing Medical  
106 Education (CME) points.<sup>11</sup>

107 This multimedia training course is aimed at building up, at a local level, a network between multidisciplinary  
108 teams dealing with melanoma and healthcare workers. In particular, this training course has been  
109 recommended to GPs, healthcare workers who are part of multidisciplinary melanoma teams and those  
110 dealing, at a local level, with the management of patients with melanoma.

111 The MelaMED programme provides the knowledge and experience that will enable participants to recognize  
112 skin lesions requiring specialist dermatological consultation by applying validated methods. Recent scientific  
113 evidence on the association between the trend of annual dermatology outpatient visit rates, skin biopsy rates  
114 and melanoma incidence rates has demonstrated a limited selection of the population at risk and of  
115 suspicious melanoma by GPs.<sup>12</sup> This epidemiological data undoubtedly represents an important basis for the  
116 implementation of specific training courses in the management of the diagnostic and therapeutic pathway  
117 of melanoma. These premises also highlight the need to carry out an evaluation of the training course and  
118 represent the rationale for this protocol.

119

## 120 **2. OBJECTIVE**

121 In the field of prevention, the expression *demonstration project* refers to projects in which a preventive tool  
122 of proven or accepted effectiveness (a dietary correction, a test for early diagnosis, etc.) is used in practice  
123 with the aim to "show something and explain how it works".<sup>13,14</sup>

124 The evaluation of these projects is essentially descriptive, and the MelaMEd programme has similar  
125 characteristics. We plan to provide a teaching activity on a large scale to a potentially very large number of  
126 subjects, i.e. in a real rather than experimental situation.

127 To establish if and how this preventive strategy works, we have identified as a primary objective the MelaMEd  
128 programme impact evaluation in terms of improvement in 1) diagnostic accuracy (recognition of suspicious  
129 lesion), 2) basic knowledge of the disease, and 3) management of suspicious lesion.

130 Our secondary objective is to gather useful information about how to enhance diagnostic accuracy and  
131 fundamental knowledge of melanoma. To address the first point, we will identify the areas in which the basic  
132 knowledge of melanoma needs to be strengthened. To address the second point, we will assess the factors  
133 that may influence the accuracy of the diagnosis and recommend appropriate intervention.

134

### 135 **3. STUDY DESIGN**

#### 136 **3.1 The MelaMEd programme**

137 The MelaMEd programme consists of a dedicated asynchronous e-learning course entitled "Early diagnosis  
138 and management of the therapeutic diagnostic pathway of melanoma". The asynchronous e-learning course  
139 includes, among the educational contents, a link to the MelaMEd platform, a website developed by IMI  
140 devoted to melanoma diagnosis and treatment. Direct access to the MelaMEd platform is possible from the  
141 asynchronous e-learning course.

142 The asynchronous e-learning course is free of charge and is delivered on behalf of the Federazione Nazionale  
143 degli Ordini dei Medici Chirurghi e degli Odontoiatri (FNOMCeO), a national association including all the  
144 Italian community of physician and dentists. The asynchronous e-learning course was activated on June 1st,  
145 2022 and available until December 31, 2023.

146 The asynchronous e-learning course has included video presentations, with audio and visual information on  
147 following topics: identification of risk groups; sun exposure pattern, photoprotection, melanoma diagnosis

148 using the mainly clinical Prediction Rules as ABCDE,<sup>15,16</sup> EFG<sup>17</sup> and the "Ugly Duckling" sign,<sup>18,19</sup>  
149 histopathological diagnosis, surgical and medical therapy and finally interactive clinical cases in the various  
150 spectrums of melanoma progression with the related decision-making points.

151 For each topic, MelaMED programme has an interactive function which allows the user to further explore  
152 any aspect of the course material available in 'switching' modality with the MelaMED platform.

153 The MelaMED programme is a real revolution in the panorama of multimedia medical training, offering  
154 interaction and integration functions connecting the asynchronous e-learning format and the MelaMED  
155 platform.

### 156 **3.2 The MelaMED platform**

157 The MelaMED platform<sup>11</sup> is a vast virtual library, a multimedia atlas, free of charge, quick to access and easy  
158 to consult. Divided into fundamental chapters containing iconographic documentation of the clinical,  
159 dermoscopic and histological aspects of melanocytic pathology, the site is geared to raising awareness of the  
160 importance of identifying melanoma at an early stage. The MelaMED platform also details surgical and  
161 medical treatments, stage and prognosis according to the latest guidelines accredited by Italian National  
162 Health Authority and by other European and international organizations.<sup>3-5</sup>

163 More specifically, the MelaMED platform is divided into 10 chapters: epidemiology, risk factors, with  
164 particular attention to ultraviolet radiation (chapters 1,2 and 3), clinical and differential diagnosis of  
165 melanoma facilitated by the use of non-invasive cutaneous techniques (chapters 4, 5, 6 and 7), histological  
166 diagnosis, medical and surgical therapy, staging, prognosis (chapters 8 and 9) and finally the most frequently  
167 asked questions from patients, with related answers (chapter 10). Each multimedia chapter includes a  
168 combination of more than one media type such as text, symbols, pictures, audio, video, with the use of static  
169 and dynamic images, as well as links to the most recent literature and the most updated official websites.

170 The MelaMED platform's contents and descriptions are listed in Table 1.

### 171 **3.3 Phases of the Study**

172 Figure 1 illustrates an outline of the project. The project is divided into the following phases: 1) presentation  
173 of the project synopsis to the IMI centers, 2) the communication of participation in the project by the IMI  
174 centers 3) the administration of a pre-training questionnaire about the basic knowledge of the disease, the

175 recognition and management of suspicious lesions, 4) the administration of the training course, 5) the  
176 administration of a post-training questionnaire to those participants who have filled in the pre-training  
177 questionnaire, and 6) the comparison of pre and post-training answers to evaluate the training course  
178 impact.

### 179 **3.4 Inclusion and exclusion criteria**

180 All GPs, resident GPs and paediatricians of the healthcare system areas of the IMI centers are eligible.  
181 Participation is optional and, in case of participation, it is mandatory for participants to provide personal data  
182 processing consent, after reading and understanding the information on the processing of personal data  
183 according to EU Regulation 679/2016. There are no exclusion criteria.

184

## 185 **4. METHODOLOGY**

### 186 **4.1 Pre-training and post-training questionnaire**

187 The pre-training questionnaire is administered to eligible participants via Google Forms. To maximize the  
188 number of eligible people filling in the questionnaire, the coordinating centre and each participating centre  
189 arrange, in several calendar dates, a webinar to present the "MelaMEd project", inviting in the meantime the  
190 participants to fill in the questionnaire. The link to the questionnaire should, therefore, be sent via email in  
191 advance. We have chosen Google Forms because it allows us to easily fill in the questionnaire via smartphone.  
192 Each eligible person will also receive a numerical code, required in both the pre and post-training  
193 questionnaires. This code is used to match the answers during the analysis.

194 The questionnaire includes 7 multiple choice theoretical questions about the prevention of skin tumours and  
195 10 images of skin tumours to be evaluated indicating 1) whether the lesion is benign or malignant, 2) one of  
196 4 possible diagnoses, 3) whether the patient should be referred to a specialist for a medical consult and  
197 possible excision (Supplementary Table 1). The 10 images of pigmented lesions have been selected according  
198 to two criteria: (1) they are present in the MelaMEd platform, and (2) they reflect pigmented lesions  
199 commonly observed in general practice. These criteria allow us to assume that the participants' diagnostic  
200 skills observed in the questionnaire can be generalized to routine medical practice.



201 In the post-training questionnaire (Supplementary Table 1), the same questions as those included in the pre-  
202 training one will be administered, together with 10 additional questions on the Likert scale for the training  
203 course global evaluation.<sup>20</sup>

#### 204 **4.2 Questionnaire validation**

205 Each question in the pre- and post-training questionnaires was extrapolated by recommendations by  
206 international publications<sup>7,17,19,21,22</sup> and by clinician guideline determinants by accredited by the National  
207 Health Institute and European organizations.<sup>3-5</sup> Furthermore, 20 people randomly chosen among those  
208 eligible have been asked via Google Forms for feedback about the clarity and understandability of each  
209 question. This methodology ensures that every respondent must, first of all, understand the question they  
210 are reading, strengthening the results.<sup>23</sup> Questions that has been evaluated include the 7 theoretical  
211 questions and the 10 questions about the images, for a total of 17 questions. For the majority (14 out of 20)  
212 of participants, all the 17 questions (100%) were asked in a clear and understandable way. For the remaining  
213 6 participants, there were from 1 to 3, out of 17, not clear and understandable questions (**Supplementary**  
214 **Table 2**). Furthermore, 9/17 questions were clear and understandable for 20 (100%) of participants, 6/17  
215 questions for the 95%, and, lastly, 2/17 questions were clear and understandable for the 90% of participants.  
216 These figures guarantee the strength of the results, once available.

#### 217 **4.3 Consent to personal data processing**

218 The project handles participants' data, including name, last name, email address and workplace. An  
219 information form will be issued to participants in accordance with EU Regulation 679/2016 regarding the  
220 processing of personal data. At the beginning of the pre-training questionnaire, participants will be asked to  
221 confirm that they have read and understood the information form above mentioned and whether they  
222 authorize their data processing. Should a respondent decline authorization, the survey will instantly end,  
223 excluding the participant from the training course impact evaluation but not preventing his/her access to the  
224 asynchronous e-learning course and to the Melamed platform. A notice is shown prior to the questionnaire  
225 automatic closure, alerting participants in case they accidentally denied permission.

226

227 **5. STATISTICAL ANALYSIS**

228 Descriptive, univariate, and multivariate analysis of the questionnaire responses will be used to assess how  
229 the training program improved the participants' diagnostic performance.

230 The percentages of correct answers for the theoretical questions given before and after the training will be  
231 compared.

232 As for the answers to the questions relating to images, we will compare the percentages of correctly  
233 diagnosed cases of benign or malignant melanoma, the percentages of right diagnoses, and the percentages  
234 of referrals to dermatologists before and after training.

235 With reference to the answers to the global evaluation questions, the frequency distribution will be  
236 calculated.

237 The Wilcoxon signed-ranks test will be used to compare the pre-training and post-training medians, and the  
238 McNemar test for paired data will be used to compare the pre-training and post-training proportions. We  
239 will use logistic regression models to investigate possible factors which might affect the accuracy of the  
240 diagnosis.

241

242 **6. DISSEMINATION**

243 Results will be published via (inter)national peer-reviewed journals and the findings of the study will be  
244 communicated using a comprehensive dissemination strategy aimed at healthcare professionals, in  
245 particular GPs, resident GPs and paediatricians.

246

247 **Informed Consent Statement**

248 There are no risks associated with this study. Individual patient consent was not required as anonymized  
249 data were used.

250

251 **Data Availability Statement**

252 The anonymized dataset used in this study is available on request from the corresponding author.

253

254 **Acknowledgments**

255 The European Institute of Oncology, Milan, Italy is partially supported by the Italian Ministry of Health with Ricerca  
256 Corrente and 5×1,000 funds.

257

258 **Working Group**

259 The FAD MelaMEd Working Group includes:

260 Maria Antonietta Pizzichetta (Aviano, Trieste), Stefania Stucci, Marco Tucci (Bari), Vincenzo De Giorgi, Daniela Massi  
261 (Firenze), Paola Ghiorzo, Cesare Massone, Enrica Tanda (Genova), Francesco de Rosa, Matelda Medri (Meldola), Roberto  
262 Patuzzo (Milano), Corrado Caracò, Marco Palla (Napoli), Alessio Fabozzi (Padova), Mario Mandalà (Perugia), Riccardo  
263 Marconcini (Pisa), Paolo Fava, Elena Marra, Pietro Quaglino, Simone Ribero (Torino) for the development of educational  
264 contents.

265

266 **References**

- 267 1. AM Forsea. Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities.  
268 Dermatol Pract Concept. 2020 Jul;10(3):e2020033.
- 269 2. Europe Beating Cancer Plan: website  
270 [https://health.ec.europa.eu/system/files/2022-02/eu\\_cancer-plan\\_en\\_0.pdf](https://health.ec.europa.eu/system/files/2022-02/eu_cancer-plan_en_0.pdf)
- 271 3. Garbe C, Amaral T, Peris K, et al; European Dermatology Forum (EDF), the European Association of  
272 Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer  
273 (EORTC). European consensus- based interdisciplinary guideline for melanoma. Part 1: Diagnostics:  
274 Update 2022. Eur J Cancer. 2022 Jul;170:236-255.
- 275 4. Garbe C, Amaral T, Peris K, et al; European Dermatology Forum (EDF), the European Association of  
276 Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer  
277 (EORTC). European consensus- based interdisciplinary guideline for melanoma. Part 2: Treatment -  
278 Update 2022. Eur J Cancer. 2022 Jul;170:256-284.
- 279 5. Linee guida Aiom accredited by ISS: website  
280 [https://www.iss.it/documents/20126/8403839/Addendum-LG\\_127\\_AIOM\\_Melanoma\\_ed2021](https://www.iss.it/documents/20126/8403839/Addendum-LG_127_AIOM_Melanoma_ed2021)
- 281 6. Linee Guida Siapec accredited by ISS - Società Italiana di Anatomia Patologica: website  
282 <https://www.siapec.it/2022/07/18/lg-snlg-lesioni-melanocitarie/>
- 283 7. AE Brown, M Najmi, T Duke et al. Skin Cancer Education Interventions for Primary Care Providers: A  
284 Scoping Review. J Gen Intern Med. 2022 Jul;37(9):2267-2279.
- 285 8. PON: documento pdf Piano Oncologico Nazionale: documento di pianificazione e indirizzo per la  
286 prevenzione e il contrasto del cancro 2023-2027: website  
287 [https://www.salute.gov.it/imgs/C\\_17\\_pubblicazioni\\_3291\\_allegato.pdf](https://www.salute.gov.it/imgs/C_17_pubblicazioni_3291_allegato.pdf)
- 288 9. Carli P, De Giorgi V, Crocetti E, et al. Diagnostic and referral accuracy of family doctors in melanoma  
289 screening: effect of a short formal training. Eur J Cancer Prev 2005;14:51–5.
- 290 10. Argenziano G, Puig S, Zalaudek I et al. Dermoscopy improves accuracy of primary care physicians to  
291 triage lesions suggestive of skin cancer. J Clin Oncol. 2006 Apr 20;24(12):1877-82.
- 292 11. MelaMEd platform: website <https://www.imi-melamed.it/>

- 293 12. L Bucchi, S Mancini, F Zamagni et al. Patient presentation, skin biopsy utilization and cutaneous  
294 malignant melanoma incidence and mortality in northern Italy: Trends and correlations. *J Eur Acad*  
295 *Dermatol Venereol.* 2022 Sep 30.
- 296 13. Grewal R, Jones R, Peters J, et al. Providing telemedicine services to persons living with HIV in an urban  
297 community: a demonstration project. *AIDS Care.* 2023 Apr 3:1-10.
- 298 14. Mai V, Flood A, Peters U, et al. Dietary fibre and risk of colorectal cancer in the Breast Cancer  
299 Detection Demonstration Project (BCDDP) follow-up cohort. *Int J Epidemiol.* 2003 Apr;32(2):234-9.
- 300 15. R J Friedman, D S Rigel, A W Kopf. Early detection of malignant melanoma: the role of physician  
301 examination and self-examination of the skin. *CA Cancer J Clin.* 1985 May-Jun;35(3):130-51.).
- 302 16. Arrington E, Clyne B, Wesseling N, et al. Diagnosing malignant melanoma in ambulatory care: a  
303 systematic review of clinical prediction rules. *BMJ Open.* 2017 Mar 6;7(3).
- 304 17. Kelly JW, Chamberlain AJ, Staples MP, McAvoy B. Nodular melanoma. No longer as simple as ABC. *Aust*  
305 *Fam Physician* 2003 Sep;32(9):706-9.
- 306 18. JJ Grob, J Bonerandi. The 'ugly duckling' sign: identification of the common characteristics of nevi in an  
307 individual as a basis for melanoma screening. *Arch Dermatol.* 1998 Jan;134(1):103-4.
- 308 19. Gaudy-Marqueste C, Wazaefi Y, Bruneu Y, et al. Ugly Duckling Sign as a Major Factor of Efficiency in  
309 Melanoma Detection. *JAMA Dermatol.* 2017 Apr 1;153(4):279-284.
- 310 20. Batterton, K. A., & Hale, K. N. (2017). The Likert Scale What It Is and How To Use It. *Phalanx*, 50(2), 32–  
311 39.
- 312 21. Grange F, Woronoff AS, Bera R, et al. Efficacy of a general practitioner training campaign for early  
313 detection of melanoma in France. *Br J Dermatol.* 2014;170(1):123-129.
- 314 22. Anders MP, Fengler S, Volkmer B, Greinert R, Breitbart EW. Nationwide skin cancer screening in  
315 Germany: Evaluation of the training program. *Int J Dermatol.* 2017;56(10):1046-1051.
- 316 23. Tourangeau R, Rips LJ, Rasinski K. *The Psychology of Survey Response (Book).* Cambridge. U.K.:  
317 Cambridge University Press, 2000. ISBN 0-5215-7246-0.
- 318
- 319


320 **Tables and figures**

321 **Table 1.** Number, name and description of the chapters included in the MelaMED platform

| Number | Name   | Description   |
|--------|--|---|
| 1      | Epidemiology                                 | Epidemiology of melanoma in terms of incidence, mortality and survival that reports the main references at international and national level   |
| 2      | Risk factors                                 | Comprehensive review of following mainly risk features: genetic, phototypes, melanocytic nevi, ABCDE and EFG rules, ugly duckling sign  |
| 3      | Sun exposure, mole and the melanoma risk     | Description of endogenous, or inherited, risk factors, and exogenous, or independent, risk factors.<br>Photo-protection and tips to ensure correct sun exposure   |
| 4      | Diagnosing melanoma                          | Explanation of self-examination importance and of the GP and dermatologist role   |
| 5      | Clinical diagnosis of melanoma               | Description and iconographic documentation of the different clinical spectrum of melanoma and special clinical forms related to degree of pigmentation and/or location  |
| 6      | Clinical differential diagnosis              | Description and iconographic documentation of the different clinical spectrum of benign melanocytic lesions (nevi) and benign or malignant non-melanocytic lesions  |
| 7      | Early diagnosis with instrumental assessment | Dermoscopy analysis and other non-invasive instrumental methods such as sequential dermoscopy, total body photography and confocal microscopy.<br>Dermoscopical and histopathological correlations. Description and iconographic documentation of the clinical and dermoscopical melanocytic nevi, melanoma and benign or malignant non-melanocytic lesions |
| 8      | Histological diagnosis                       | Histopathological and molecular diagnosis of melanoma and melanocytic lesions recommended by <i>WHO Classification of Skin Tumours</i> 4th edition  |
| 9      | Surgery, staging, prognosis and treatment    | Comprehensive review of surgical treatment, staging, prognosis, follow-up and treatment topics  |
| 10     | Questions patients ask                       | List of the most frequently asked questions from patients, with the related answers   |

322 GP, General practitioner

323 **Figure 1.** Name and description of the study phases



324

325

326 **Supplementary material**

327 **Supplementary Table 1.** Question and answers of the pre-training and post-training questionnaires. The  
328 right answer is underlined

| Question number                          | Question text   | Multiple choice answer   |
|--|---|--|
| <i>Consent and demographic questions</i> |   |  |
| 1  | In accordance with EU Regulation 679/2016 regarding personal data protection, do you consent to the processing of your personal data? | a) Yes<br>b) No  |
| 2  | Select your job title   | a) General Practitioner<br>b) Resident General Practitioner<br>c) Paediatrician  |
| 3  | What age group do you belong to?  | a) <40<br>b) 40-60<br>c) >60   |
| <i>Theoretical questions</i>             |   |  |
| 1*                                       | Which of the following is a risk factor for melanoma?   | a) <u>Ultraviolet radiation</u><br>b) Cigarette smoke<br>c) Consumption of red meat<br>d) Alcohol abuse  |
| 2*                                       | What is needed for a complete visual examination of the skin?   | a) Evaluation only of the suspected neof ormation reported by the patient<br>b) Live evaluation of the entire skin area in dim light<br>c) <u>Live evaluation of the entire skin area in optimal lighting conditions and with the use of a magnifying glass</u><br>d) Referral to the specialist reference centre  |
| 3*                                       | What does the ABCDE acronym for the recognition of a suspected melanoma mean?   | a) Asymmetry, Regular edges, Homogeneous colour, Dimensions <2 mm, Empathy<br>b) Asymmetry, Irregular edges, Homogeneous colour, Dimensions <5 mm, Static evolution<br>c) <u>Asymmetry, Irregular edges, Uneven colour, Dimensions &gt;6 mm, rapid Evolution</u><br>d) Asymmetry, Irregular edges, Homogeneous color, Small dimensions, Entropy<br>e) I don't know the ABCDE acronym |
| 4*                                       | What does the EFG rule coined by Australian dermatologists for the recognition of suspected nodular melanoma mean?                    | a) Erythema, Firm, Ground<br>b) <u>Elevation, Firm, Growth</u><br>c) Evolution, Figure, Great dimension<br>d) Extension, Family history, Great dimension<br>e) I don't know the EFG rule   |
| 5*                                       | What is meant by the "ugly duckling" sign for recognizing a suspected melanoma?   | a) Homogeneous nevus equal to other nevus in shape and color<br>b) Nevus regular compared to other nevus<br>c) Moriform congenital nevus<br>d) <u>Different nevus that "stands out" compared to other nevus due to its shape, color and/or rapid evolution</u>   |



|               |  |   |
|---------------|--|---|
|               |  | e) I don't know the sign of the "ugly duckling"   |
| 6*            | Which of the following statements about dermoscopy is true?        | <p>a) <u>Dermoscopy is a non-invasive technique that allows the in vivo evaluation of skin colors and structures not visible to the naked eye</u></p> <p>b) Dermoscopy is a non-invasive technique that uses a laser beam with a near-infrared wavelength (830 nm), to evaluate the cells of the superficial layer of the skin at a depth of approximately 100-200 <math>\mu\text{m}</math></p> <p>c) Dermoscopy is an incisional biopsy specific for melanocytic lesions</p> <p>d) Dermoscopy can replace histological examination</p>   |
| 7*            | Which of the following statements about Breslow thickness is true? | <p>a) It indicates the degree of invasion of the skin. It is divided into 5 levels based on the degree of infiltration: from I (melanoma in situ) to V (infiltration of the entire dermis up to the adipose tissue)</p> <p>b) <u>It indicates the thickness of the melanoma from the granular layer of the skin (or from the base of the ulcer if the lesion is ulcerated) to the point of maximum infiltration into the dermis. It is measured in mm</u></p> <p>c) It indicates whether the melanoma is in the horizontal or vertical histological phase</p> <p>d) It indicates the depth of tumor-infiltrating lymphocytes (TILs)</p> |
| <i>Images</i> |  |   |
| 1*            | Consider the following pigmented lesion, indicate if it is:        | <p>a) Benign</p> <p>b) Malignant</p> <p>c) I don't know</p>   |
|               | Would you refer the patient to a dermatologist?                    | <p>a) Yes</p> <p>b) No</p>  |
|               | Which is your diagnosis?   | <p>a) Common Nevus</p> <p>b) Atypical Nevus</p> <p>c) <u>Melanoma</u></p> <p>d) Seborrheic Keratosis</p>  |
| 2*            | Consider the following pigmented lesion, indicate if it is:        | <p>a) Benign</p> <p>b) Malignant</p> <p>c) I don't know</p>   |
|               | Would you refer the patient to a dermatologist?                    | <p>a) Yes</p> <p>b) No</p>  |
|               | Which is your diagnosis?   | <p>a) Seborrheic Keratosis</p> <p>b) Common Nevus</p> <p>c) <u>Congenital Nevus</u></p> <p>d) Melanoma</p>  |
| 3*            | Consider the following pigmented lesion, indicate if it is:        | <p>a) Benign</p> <p>b) Malignant</p> <p>c) I don't know</p>   |

|    |   |  |
|----|---|--|
|    | Would you refer the patient to a dermatologist?             | a) Yes<br>b) No  |
|    | Which is your diagnosis?                                    | a) <u>Seborrheic Keratosis</u><br>b) Common Nevus<br>c) Atypical Nevus<br>d) Melanoma            |
| 4* | Consider the following pigmented lesion, indicate if it is: | a) Benign<br>b) Malignant<br>c) I don't know   |
|    | Would you refer the patient to a dermatologist?             | a) Yes<br>b) No  |
|    | Which is your diagnosis?                                    | a) Seborrheic Keratosis<br>b) Common Nevus<br>c) Congenital Nevus<br>d) <u>Melanoma</u>          |
| 5* | Consider the following pigmented lesion, indicate if it is: | a) Benign<br>b) Malignant<br>c) I don't know   |
|    | Would you refer the patient to a dermatologist?             | a) Yes<br>b) No  |
|    | Which is your diagnosis?                                    | a) Congenital Nevus<br>b) <u>Melanoma</u><br>c) Seborrheic Keratosis<br>d) Basal cell carcinoma  |
| 6* | Consider the following pigmented lesion, indicate if it is: | a) Benign<br>b) Malignant<br>c) I don't know   |
|    | Would you refer the patient to a dermatologist?             | a) Yes<br>b) No  |
|    | Which is your diagnosis?                                    | a) <u>Melanocytic Nevus</u><br>b) Basal cell carcinoma<br>c) Melanoma<br>d) Seborrheic Keratosis |
| 7* | Consider the following pigmented lesion, indicate if it is: | a) Benign<br>b) Malignant<br>c) I don't know   |
|    | Would you refer the patient to a dermatologist?             | a) Yes<br>b) No  |
|    | Which is your diagnosis?                                    | a) Atypical Nevus<br>b) <u>Congenital Nevus</u><br>c) Melanoma<br>a) Basal cell carcinoma        |
| 8* | Consider the following pigmented lesion, indicate if it is: | a) Benign<br>b) Malignant<br>c) I don't know   |
|    | Would you refer the patient to a dermatologist?             | a) Yes<br>b) No  |
|    | Which is your diagnosis?                                    | a) Melanocytic Nevus<br>b) Angioma<br>c) <u>Melanoma</u><br>d) Basal Cell Carcinoma              |

|                                    |  |   |
|------------------------------------|--|---|
| 9*                                 | Consider the following pigmented lesion, indicate if it is:  | a) Benign<br>b) Malignant<br>c) I don't know  |
|                                    | Would you refer the patient to a dermatologist?  | a) Yes<br>b) No   |
|                                    | Which is your diagnosis?   | a) Solar Lentigo<br>b) Seborrheic Keratosis<br>c) Congenital Nevus<br>d) <u>Malignant Lentigo</u>           |
| 10*                                | Consider the following pigmented lesion, indicate if it is:  | a) Benign<br>b) Malignant<br>c) I don't know  |
|                                    | Would you refer the patient to a dermatologist?  | a) Yes<br>b) No   |
|                                    | Which is your diagnosis?   | a) Seborrheic Keratosis<br>b) <u>Basal Cell Carcinoma</u><br>c) Congenital Nevus<br>d) Melanoma             |
| <i>Global evaluation questions</i> |  |   |
| 1*                                 | How confident do you feel in giving patients information on the primary prevention of skin cancer? | a) Absolutely not confident<br>b) Not confident<br>c) Don't know<br>d) Confident<br>e) Absolutely confident |
| 2*                                 | How confident do you feel in informing the patient about the skin self-examination?                | a) Absolutely not confident<br>b) Not confident<br>c) Don't know<br>d) Confident<br>e) Absolutely confident |
| 3*                                 | How confident do you feel in making a diagnosis of a suspected melanoma?                           | a) Absolutely not confident<br>b) Not confident<br>c) Don't know<br>d) Confident<br>e) Absolutely confident |
| 4**                                | Do you think MelaMEd has improved your ability to recognize patients at high risk of melanoma?     | a) Absolutely disagree<br>b) Disagree<br>c) Don't know<br>d) Agree<br>e) Absolutely agree                   |
| 5**                                | Do you think MelaMEd has improved your ability to distinguish melanoma from benign lesions?        | a) Absolutely disagree<br>b) Disagree<br>c) Don't know<br>d) Agree<br>e) Absolutely agree                   |
| 6**                                | Do you think MelaMEd has improved your knowledge in skin cancer management?                        | a) Absolutely disagree<br>b) Disagree<br>c) Don't know<br>d) Agree<br>e) Absolutely agree                   |
| 7**                                | Do you prefer multimedia training based on the MelaMEd model to traditional live training?         | a) Absolutely disagree<br>b) Disagree<br>c) Don't know  |

|      |   |   |
|------|---|---|
|      |   | d) Agree<br>e) Absolutely agree   |
| 8**  | Do you think that the active participation of GPs, resident GPs and paediatricians can improve the early diagnosis of melanoma? | a) Absolutely disagree<br>b) Disagree<br>c) Don't know<br>d) Agree<br>e) Absolutely agree |
| 9**  | Would you be interested in attending a dermoscopy course?   | a) Yes<br>b) No   |
| 10** | Would you like to receive additional information about melanoma on a regular basis?   | a) Yes<br>b) No   |

329 GP, General practitioner;

330 \*, question present both in pre-training and post-training questionnaire

331 \*\*, question present only in the post-training questionnaire

332

333 **Supplementary Table 2.** Distribution of the number of clear and understandable questions from the pre  
334 and post-training questionnaire. Questions that has been evaluated include the 7 theoretical questions and  
335 the 10 questions about the images, for a total of 17 questions.

| Participants | Clear and understandable questions<br>N(%) | Not clear and understandable questions<br>N(%) |
|--------------|--|--|
| 14           | 17 (100)                                   | 0 (0)  |
| 3            | 16 (94)                                    | 1 (6)  |
| 2            | 15 (88)                                    | 2 (12)   |
| 1            | 14 (82)                                    | 3 (18)   |

336

337

338

339